基本信息
浏览量:319
职业迁徙
个人简介
Dr. William (Bill) Barry has devoted his career to clinical research and efforts to efficiently and rigorously test novel therapeutics and innovative strategies to improve health outcomes in a variety of disease settings.
Dr. Barry has more than 12 years of experience in Phase 1-3 clinical trials and translational research efforts to discover and validate genomic and proteomic signatures of diseases and molecular measures in response to interventions.
In 2010 while at the Institute for Genome Science and Policy at Duke University, Dr. Barry participated in a large federally-funded collaborative project in order to validate genomic signatures of the host response to the H1N1 virus and to evaluate the platform as a novel approach to diagnosis and detection of infection. At the Duke Cancer Institute and later at the Dana-Farber Cancer Institute, Dr. Barry supported multiple early-phase investigations into whether vaccines can be a novel and promising approach to targeted therapies as well as the enhancement of immune responses in breast cancer.
Rho’s cross-disciplinary and team-based approach to clinical research has been a strong motivator for Dr. Barry in a wide array of activities. Most recently, Dr. Barry participated in the design and conduct of trials for medical and infectious disease countermeasures under the Biomedical and Advanced Research Development Authority (BARDA).
Core Aims:
Provide biostatistical and computational biology expertise for the planning and design, conduct, analysis, and reporting of laboratory, genomic, animal, translational, clinical (including associated correlative studies), and epidemiological studies for SPORE Projects, Developmental Research and Career Development projects, and other SPORE Cores.
Provide consultation on all issues of data management and integrity, including data collection, storage, transfer and quality assurance, on statistical and computational biology software and programs, and on coordination of laboratory results with parameters and outcomes from clinical studies or clinical/translational research databases.
Provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers.
Dr. Barry has more than 12 years of experience in Phase 1-3 clinical trials and translational research efforts to discover and validate genomic and proteomic signatures of diseases and molecular measures in response to interventions.
In 2010 while at the Institute for Genome Science and Policy at Duke University, Dr. Barry participated in a large federally-funded collaborative project in order to validate genomic signatures of the host response to the H1N1 virus and to evaluate the platform as a novel approach to diagnosis and detection of infection. At the Duke Cancer Institute and later at the Dana-Farber Cancer Institute, Dr. Barry supported multiple early-phase investigations into whether vaccines can be a novel and promising approach to targeted therapies as well as the enhancement of immune responses in breast cancer.
Rho’s cross-disciplinary and team-based approach to clinical research has been a strong motivator for Dr. Barry in a wide array of activities. Most recently, Dr. Barry participated in the design and conduct of trials for medical and infectious disease countermeasures under the Biomedical and Advanced Research Development Authority (BARDA).
Core Aims:
Provide biostatistical and computational biology expertise for the planning and design, conduct, analysis, and reporting of laboratory, genomic, animal, translational, clinical (including associated correlative studies), and epidemiological studies for SPORE Projects, Developmental Research and Career Development projects, and other SPORE Cores.
Provide consultation on all issues of data management and integrity, including data collection, storage, transfer and quality assurance, on statistical and computational biology software and programs, and on coordination of laboratory results with parameters and outcomes from clinical studies or clinical/translational research databases.
Provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers.
研究兴趣
论文共 361 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Joyce F. Liu,Niya Xiong,Robert M. Wenham,Andrea Wahner-Hendrickson,Deborah K. Armstrong,Nancy Chan,David M. O'Malley,Jung-Min Lee,Richard T. Penson,Mihaela C. Cristea,James L. Abbruzzese,Koji Matsuo,Alexander B. Olawaiye,William T. Barry,Su-Chun Cheng,Madeline Polak,Elizabeth M. Swisher,Geoffrey I. Shapiro,Elise C. Kohn,S. Percy Ivy
Gynecologic oncology (2024): 105-112
Angeles Alvarez Secord, Deanna K. Teoh,William T. Barry, Miao Yu,Gloria Broadwater,Laura J. Havrilesky,Paula S. Lee,Andrew Berchuck, Johnathan M. Lancaster,Robert M. Wenham
openalex(2023)
crossref(2023)
semanticscholar(2023)
Manish Neupane,Allison P. Clark,Serena Landini, Nicolai J. Birkbak,Aron C. Eklund,Elgene Lim,Aedin C. Culhane,William T. Barry,Steven E. Schumacher,Rameen Beroukhim,Zoltan Szallasi,Marc Vidal,David E. Hill, Daniel P. Silver
semanticscholar(2023)
crossref(2023)
openalex(2023)
Cancerno. 14 (2023): 2135-2143
crossref(2023)
crossref(2023)
加载更多
作者统计
#Papers: 351
#Citation: 13489
H-Index: 59
G-Index: 110
Sociability: 8
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn